PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes

16-Sep-2024 - PhoreMost Ltd. announced it has added USD $12 million to its Series B financing, bringing the total raised to over $50 million. The additional investment was led by Parkwalk Advisors, the largest growth EIS fund manager, with participation from existing investors BGF, Dr Jonathan Milner, Amadeus ...

PhoreMost enters multi-target collaboration with Arvinas

PhoreMost to deploy its SITESEEKER Targeted Protein Degradation platform to enable drug discovery against multiple therapeutic targets

03-Nov-2022 - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has entered into a multi-target collaboration with Arvinas, an industry leader in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will ...

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

Start-ups combine biotechnology and artificial intelligence

06-Jan-2022 - PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, announced a collaborationto study oncology targets currently considered ...

PhoreMost closes £33M Series B financing

Start-up is advancing its pipeline of novel therapies for oncology and diseases of ageing

25-Mar-2021 - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s most active growth economy investor, and included new investors ...